Dactolisib

DB11651InvestigationalSmall molecule

Dactolisib has been used in trials studying the treatment of Cancer, Solid Tumor, Renal Cancer, Breast Cancer, and Cowden Syndrome, among others.

Chemical structure of Dactolisib
Mechanism
Curator reviewed
Formula / weight
C30H23N5O · 469.548 g/mol (avg)
Code names
BEZ-235 · RTB101

Resolves to

Compound
UNIIRUJ6Z9Y0DTCAS915019-65-7ChEMBLCHEMBL1879463ChEBI71952PubChem11977753
Structure
InChIKeyJOGKUKXHTYWRGZ-UHFFFAOYSA-NSMILESCN1C(=O)N(C2=C1C=NC1=CC=C(C=C21)C1=CN=C2C=CC=CC2=C1)C1=CC=C(C=C1)C(C)(C)C#N
Targets
P42345MTORP48736PIK3CG

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
39Drug interactionsStructured to mechanism, not free text
Sign in
26Clinical trialsPhase, status and sponsor resolved per trial
Sign in
11+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Dactolisib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In